We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


CIDR to Use Illumina Whole-Genome Genotyping Solutions

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "CIDR to Use Illumina Whole-Genome Genotyping Solutions"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Illumina, Inc. has announced that it is partnering with the Center for Inherited Disease Research (CIDR) to use the Sentrix® HumanHap300 BeadChip and Infinium™ Assay for a pilot study of Type 2 Diabetes.

One goal of this study is to evaluate the Illumina technology for possible adoption as the standard platform for CIDR's genome-wide association service to be offered to the scientific community in the spring of 2006.

CIDR is working with Illumina to genotype over 2500 case-control samples provided by the Finland-United States Investigation of NIDDM Genetics (FUSION) Study, an international research collaboration.

Funded by the National Institutes of Health (NIH), the goal of the FUSION team is to map and identify genetic variants that predispose individuals to Type 2 diabetes (formerly non-insulin-dependent diabetes mellitus, or NIDDM).

As part of its technology evaluation efforts, CIDR will use the Sentrix HumanHap300 BeadChip to query over 317,000 tagSNPs on a single microarray device.

The BeadChip is powered by Illumina's Infinium assay, which enables the intelligent selection and analysis of virtually any SNP in the genome.

Illumina claims that, the high statistical value of the SNP loci in the HumanHap300 enables researchers to achieve the comprehensive genomic coverage of any array on the market.

According to David Valle, M.D., Director, CIDR and Professor, Institute of Genetic Medicine, Johns Hopkins University, "CIDR is committed to serving the genetics research community by providing the most powerful technology in its genotyping service laboratory."

"This pilot study gives us an opportunity to investigate and evaluate a promising genotyping platform that takes advantage of HapMap DNA markers that were designed to maximize our ability to identify associations between diseases and particular DNA variants."

"We chose Type 2 diabetes for this evaluation effort because of the wealth of existing genetic data about the disease and the strength of the statistical and analytical expertise of the investigators involved in the FUSION project."

"We are looking forward to working with Illumina and the diabetes team to bring this pilot project to a successful and rapid conclusion."

Commenting further on the study, Jay Flatley, Illumina CEO and President, stated, "The identification of tagSNPs in the HapMap Project has laid the groundwork for a follow-on stream of large-scale disease association studies."

"We're excited to see significant genotyping data being generated using our new HumanHap300 BeadChip, as the content of this chip was developed collaboratively with key HapMap participants."

"We're eager to work with the CIDR and FUSION teams on the Type 2 diabetes study."